Bio-Rad Labs (NYSE: BIO) reported Q1 EPS of $1.89, $0.05 better than the analyst estimate of $1.84. Revenue for the quarter came in at $592.1 million versus the consensus estimate of $586.97 million.

Bio-Rad is updating its financial outlook for the full-year 2026. The Company currently expects non-GAAP, currency-neutral revenue to be in the range of a decline of approximately 3.0 percent to growth of approximately 0.5 percent, compared to its prior expectation of growth of approximately 0.5 to 1.5 percent. The Company also expects an estimated non-GAAP operating margin of approximately 10.0 to 12.0 percent compared to its prior estimate of approximately 12.0 to 12.5 percent.

For earnings history and earnings-related data on Bio-Rad Labs (BIO) click here.